First HCFA Coverage Panel To Review Stem Cell Transplantation
This article was originally published in The Gray Sheet
Executive Summary
High dose chemotherapy and stem cell transplantation combination treatment for multiple myeloma will be reviewed Sept. 15-16 by the Health Care Financing Administration Medicare Coverage Advisory Committee's drugs, biologics and therapeutics panel, an Aug. 13 Federal Register notice states.
You may also be interested in...
Rochester Medical FemSoft Incontinence Insert Among FY 1999's 33 PMAs
FDA approval of Rochester Medical's FemSoft insert for female stress urinary incontinence on Sept. 30, the final day of the federal government's fiscal year, apparently put the agency's total number of approved, original premarket approval applications for the year at 33, down from 42 in 1998 and 46 in 1997.
Rochester Medical FemSoft Incontinence Insert Among FY 1999's 33 PMAs
FDA approval of Rochester Medical's FemSoft insert for female stress urinary incontinence on Sept. 30, the final day of the federal government's fiscal year, apparently put the agency's total number of approved, original premarket approval applications for the year at 33, down from 42 in 1998 and 46 in 1997.
One-Third Of HCFA DME Panel Appointees Backed By Congressmen
Three of the nine voting members named to the durable medical equipment panel of the Health Care Financing Administration's Medicare Coverage Advisory Committee received congressional support in their bid for appointment.